foretinib (GSK1363089)

News alerts, weekly reports and conference planners

Company:

Exelixis

Drug class:

c-MET inhibitor, VEGFR-2 inhibitor

MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	GSK1363089 Sensitive: C3 – Early Trials GSK1363089 Sensitive : C3	GSK1363089 Sensitive: C3 – Early Trials GSK1363089 Sensitive : C3
BCR-ABL1 V299L	Acute Lymphocytic Leukemia	BCR-ABL1 V299L	Acute Lymphocytic Leukemia	GSK1363089 Sensitive: D – Preclinical GSK1363089 Sensitive : D	GSK1363089 Sensitive: D – Preclinical GSK1363089 Sensitive : D

Associations
(2)